Page 1
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1 )
Pharmaceutical Marketing Services
(Name of Issuer)
Common Stock
(Title of Class of Securities)
717123103
(CUSIP Number)
Charles A. Nalbone, Bear, Stearns & Co. Inc.
115 South Jefferson Road, Whippany, NJ 07981
(973) 793-2202
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
May 17, 1999
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule
13G to report the acquisition which is the subject of this Schedule 13D,
and is filing this schedule because of Rule 13d-1(b) (3) or (4), check the
following box [ ] .
Check the following box if a fee is being paid with this statement
[ ] . (A fee is not required only if the reporting person: 1) has a
previous statement on file reporting beneficial ownership of more than
five percent of the class of securities described in Item 1; and 2) has
filed no amendment subsequent thereto reporting beneficial ownership of five
percent or less of such class. (See Rule 13d-7)
Note: When filing this statement, in paper format, six copies of
this statement, including exhibits, should be filed with the Commission.
See Rule 13d-1(a) for other parties to whom copies are to be sent.
Page 2
CUSIP NO. 717123103
13D
NAME OF REPORTING PERSON
S.S. OR I.R.S. NOTIFICATION NO. OF ABOVE PERSON:
1 BEAR, STEARNS & CO. INC.
IRS #13-3299429
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*:
(a) [ ]
(b) [ ]
3 SEC USE ONLY
4 SOURCE OF FUNDS*:
WC, PF
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d)(e):
[ ]
6 CITIZENSHIP OR PLACE OF ORGANIZATION:
Delaware
7 SOLE VOTING POWER:
0
8 SHARED VOTING POWER:
0
9 SOLE DISPOSITIVE POWER:
0
10 SHARED DISPOSITIVE POWER:
0
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
0
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES*:
[ ]
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):
0.0
14 TYPE OF REPORTING PERSON*:
BD
See Instructions Before Filling Out!
Page 3
Schedule 13D Amendment No. 1
This statement constitutes Amendment No. 1 to the statement on Schedule 13D
(the "Schedule 13D") filed with the Securities and Exchange Commission by Bear,
Stearns & Co. Inc. ("Bear Stearns") with respect to its ownership of the Common
Stock of Pharmaceutical Marketing Services (the "Issuer").
Item 3: Source and Amount of Funds or Other Consideration
Not applicable.
Item 5: Interest in Securities of the Issuer (as of 05/17/99)
(a) The responses of Bear Stearns to Rows (11) through (13) of the
cover page of this Amendment No. 1 to Schedule 13D are
incorporated herein by reference. To the best of Bear Stearns'
knowledge, none of its executive officers or directors
beneficially own any Common Stock of the Issuer.
(b) The responses of Bear Stearns to Rows (7) through (10) of the
cover page of this Amendment No. 1 to Schedule 13D are
incorporated herein by reference.
(c) Since the date of its initial filing on Schedule 13D, Bear
Stearns has effected transactions in the Common Stock of the
Issuer. Information concerning transactions in the Common Stock
effected by Bear Stearns is set forth on Appendix I.
(d) Not Applicable.
(e) On May 17, 1999, Quintiles Transnational.(QTRNC) completed its
acquisition of Pharmaceutical Marketing Services (PMRX). According to the
terms of the acquisition, Bear Stearns exchanged its holdings of 654,097
shares of Pharmaceutical Marketing Services for 260,153 shares of Quintiles
Transnational. Therefore, Bear Stearns ceased to be the beneficial
owner of more than five percent of the Common Stock of the Issuer since
the date of its original filing.
Page 4
Signature:
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true,
complete and correct.
Dated: May 19, 1999 BEAR, STEARNS & CO. INC.
By: /s/
Barry Cohen
Senior Managing Director
APPENDIX I
BEAR, STEARNS & CO. INC.
Pharmaceutical Marketing Services.
Trades from 05/17/99 through 05/17/99
(Various Firm Accounts)
***** 05/17 *****
557,209- PHARMACEUTICAL MARKETING XCH OP .00
SERVICES INC
5,721- PHARMACEUTICAL MARKETING XCH OP .00
SERVICES INC
400- PHARMACEUTICAL MARKETING XCH OP .00
SERVICES INC
400- PHARMACEUTICAL MARKETING XCH OP .00
SERVICES INC
600- PHARMACEUTICAL MARKETING XCH OP .00
SERVICES INC
1,000- PHARMACEUTICAL MARKETING XCH OP .00
SERVICES INC
12,604- PHARMACEUTICAL MARKETING XCH OP .00
SERVICES INC
1,400- PHARMACEUTICAL MARKETING XCH OP .00
SERVICES INC
750- PHARMACEUTICAL MARKETING XCH OP .00
SERVICES INC
750- PHARMACEUTICAL MARKETING XCH OP .00
SERVICES INC
1,400- PHARMACEUTICAL MARKETING XCH OP .00
SERVICES INC
4,122- PHARMACEUTICAL MARKETING XCH OP .00
SERVICES INC
19,525- PHARMACEUTICAL MARKETING XCH OP .00
SERVICES INC
46,816- PHARMACEUTICAL MARKETING XCH OP .00
SERVICES INC
1,400- PHARMACEUTICAL MARKETING XCH OP .00
SERVICES INC
